Search results for "diabetes mellitu"

showing 10 items of 2088 documents

Complications of Diabetes 2017

2018

0301 basic medicinemedicine.medical_specialtyArticle SubjectDiabetic CardiomyopathiesEndocrinology Diabetes and MetabolismMEDLINEDiabetic angiopathylcsh:Diseases of the endocrine glands. Clinical endocrinologyDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusDiabetic cardiomyopathymedicineAnimalsHumans030212 general & internal medicineIntensive care medicinelcsh:RC648-665business.industrymedicine.diseaseEditorial030104 developmental biologybusinessDiabetic AngiopathiesIntroductory Journal ArticleJournal of Diabetes Research
researchProduct

Systemic treatment of HCC in special populations

2020

Summary Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirr…

0301 basic medicinemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityDisease03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansMultiple Chronic ConditionsAutoimmune diseaseHepatologybusiness.industryLiver NeoplasmsConfoundingDisease ManagementImmunotherapymedicine.diseasedigestive system diseasesPortal vein thrombosis030104 developmental biologyHepatocellular carcinoma030211 gastroenterology & hepatologyMetabolic syndromebusinessJournal of Hepatology
researchProduct

Expert opinion on the metabolic complications of mTOR inhibitors

2018

Abstract Using mTOR inhibitors (mTORi) as anticancer drugs led to hyperglycemia (12–50%) and hyperlipidemia (7–73%) in phase-III trials. These high rates require adapted treatment in cancer patients. Before initiating mTORi treatment, lipid profile screening should be systematic, with fasting glucose assay in non-diabetic patients and HbA1C in diabetic patients. After initiation, lipid profile monitoring should be systematic, with fasting glucose assay in non-diabetic patients, every 2 weeks for the first month and then monthly. The HbA1C target is ≤ 8%, before and after treatment initiation in known diabetic patients and in case of onset of diabetes under mTORi. LDL-cholesterol targets sho…

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismAtorvastatinAntineoplastic Agents03 medical and health sciences0302 clinical medicineEndocrinologyMetabolic DiseasesNeoplasmsInternal medicineDiabetes mellitusHyperlipidemiamedicineHumansDyslipidemiasFenofibratemedicine.diagnostic_testbusiness.industryTOR Serine-Threonine KinasesHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemia030104 developmental biologySimvastatin030220 oncology & carcinogenesislipids (amino acids peptides and proteins)Lipid profilebusinessPravastatinmedicine.drugAnnales d'Endocrinologie
researchProduct

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

2020

ABSTRACT Introduction The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discu…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismType 2 diabetesSaxagliptinLinagliptinIncretins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansHypoglycemic AgentsVildagliptinDipeptidyl-Peptidase IV InhibitorsPancreatitiHypoglycemic Agentbusiness.industryPancreatic NeoplasmIncretinmedicine.diseasePancreatic NeoplasmsTreatment Outcome030104 developmental biologyDiabetes Mellitus Type 2PancreatitischemistryTolerabilitySitagliptinDipeptidyl-Peptidase IV InhibitorbusinessAlogliptinHumanmedicine.drugMetabolism
researchProduct

Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?

2018

Secondary adrenal insufficiency (SAI) is a potentially life-threatening endocrine disorder due to an impairment of corticotropin (ACTH) secretion from any process affecting the hypothalamus or pituitary gland. ACTH deficit can be isolated or associated with other pituitary failures (hypopituitarism). An increased mortality due to cardiovascular, metabolic, and infectious diseases has been described in both primary and secondary adrenal insufficiency. However, few studies have provided compelling evidences on the underlying mechanism in SAI, because of the heterogeneity of the condition. Recently, some studies suggested that inappropriate glucocorticoid (GCs) replacement therapy, as for dose…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMini Reviewbody mass index; diabetes mellitus; glucocorticoids; impaired glucose tolerance; insulin resistance; metabolic syndrome; secondary adrenal insufficiency; weight gain030209 endocrinology & metabolismbody mass indexHypopituitarismlcsh:Diseases of the endocrine glands. Clinical endocrinologymetabolic syndromeGrowth hormone deficiencyImpaired glucose tolerance03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineDiabetes mellitusinsulin resistanceMedicineEndocrine systemlcsh:RC648-665glucocorticoidsbusiness.industryweight gainmedicine.disease030104 developmental biologyEndocrinologyimpaired glucose tolerancediabetes mellitussecondary adrenal insufficiencyMetabolic syndromebusinessGlucocorticoidmedicine.drug
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct

Relationship between PMN-endothelium interactions, ROS production and Beclin-1 in type 2 diabetes.

2020

Type 2 diabetes is closely related to oxidative stress and cardiovascular diseases. In this study, we hypothesized that polymorphonuclear leukocytes (PMN)-endothelium interactions and autophagy are associated. We evaluated PMN-endothelial interactions, ROS production and autophagy parameters in 47 type 2 diabetic patients and 57 control subjects. PMNs from type 2 diabetic patients exhibited slower rolling velocity (p < 0.001), higher rolling flux (p < 0.001) and adhesion (p < 0.001) in parallel to higher levels of total (p < 0.05) and mitochondrial ROS (p < 0.05). When the protein expression of autophagy markers was analysed, an increase of Beclin-1 (p < 0.05), LC3I (p < 0.05), LC3II (p < 0…

0301 basic medicinemedicine.medical_specialtyEndotheliumNeutrophilsClinical BiochemistryType 2 diabetesMitochondrionmedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicineAutophagyCell AdhesionHumansEndotheliumlcsh:QH301-705.5lcsh:R5-920ChemistryOrganic ChemistryAutophagyRolling velocityType 2 diabetesROSmedicine.diseaseControl subjectsMitochondria030104 developmental biologymedicine.anatomical_structureEndocrinologylcsh:Biology (General)Diabetes Mellitus Type 2Oxidative stressCase-Control StudiesPMN-Endothelium interactionsBeclin-1lcsh:Medicine (General)Reactive Oxygen Species030217 neurology & neurosurgeryOxidative stressResearch PaperRedox biology
researchProduct

Influence of mental stress and environmental toxins on circadian clocks : implications for redox regulation of the heart and cardioprotection

2020

Risk factors in the environment such as air pollution and mental stress contribute to the development of chronic non-communicable disease. Air pollution was identified as the leading health risk factor in the physical environment, followed by water pollution, soil pollution/heavy metals/chemicals and occupational exposures, however neglecting the non-chemical environmental health risk factors (e.g. mental stress and noise). Epidemiological data suggest that environmental risk factors are associated with higher risk for cardiovascular, metabolic and mental diseases, including hypertension, heart failure, myocardial infarction, diabetes, arrhythmia, stroke, depression and anxiety disorders. W…

0301 basic medicinemedicine.medical_specialtyExposomeCircadian clock610 MedizinReview ArticleDiseaseCardiovascular System03 medical and health sciences0302 clinical medicineCircadian ClocksDiabetes mellitusEnvironmental health610 Medical sciencesEpidemiologymedicineHumansReview ArticlesStrokeDepression (differential diagnoses)Pharmacologybusiness.industryHeartmedicine.disease3. Good health030104 developmental biology13. Climate actionHypertensionAnxietymedicine.symptombusinessOxidation-Reduction030217 neurology & neurosurgery
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

1,4-Dihydropyridine derivatives without Ca2+-antagonist activity up-regulatePsma6mRNA expression in kidneys of intact and diabetic rats

2015

Impaired degradation of proteins by the ubiquitin-proteasome system (UPS) is observed in numerous pathologies including diabetes mellitus (DM) and its complications. Dysregulation of proteasomal degradation might be because of altered expression of genes and proteins involved in the UPS. The search for novel compounds able to normalize expression of the UPS appears to be a topical problem. A novel group of 1,4-dihydropyridine (1,4-DHP) derivatives lacking Ca2+-antagonists activities, but capable to produce antidiabetic, antioxidant and DNA repair enhancing effects, were tested for ability to modify Psma6 mRNA expression levels in rat kidneys and blood in healthy animals and in rats with str…

0301 basic medicinemedicine.medical_specialtyKidneyAntioxidantmedicine.medical_treatmentClinical BiochemistryCell BiologyGeneral MedicineBiologyStreptozotocinmedicine.diseaseBiochemistry03 medical and health sciences030104 developmental biologyReal-time polymerase chain reactionmedicine.anatomical_structureEndocrinologyDownregulation and upregulationInternal medicineDiabetes mellitusGene expressionmedicineGenemedicine.drugCell Biochemistry and Function
researchProduct